Patents by Inventor Christopher Kallus

Christopher Kallus has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Macrocyclic urea derivatives as inhibitors of TAFIa, their preparation and their use as pharmaceuticals
    Patent number: 9834527
    Abstract: The present invention relates to macrocydic urea derivatives of the formula I (I) in which R1, R2, R3, V and Y are as defined below. The compounds of the formula I are inhibitors of the enzyme TAFIa (activated thrombin-activatable fibrinolysis inhibitor). The invention further relates to the process for the preparation of the compounds of formula I and to the use thereof as medicaments.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: December 5, 2017
    Assignee: SANOFI
    Inventors: Andreas Evers, Christopher Kallus, Michael Wagner, Hermut Wehlan
  • Macrocyclic urea and sulfamide derivatives as inhibitors of TAFIa
    Patent number: 9688645
    Abstract: The invention relates to compounds of the formula (I) which are inhibitors of activated thrombin-activable fibrinolysis inhibitor. The compounds of the formula I are suitable for producing medicaments for prophylaxis, secondary prevention and treatment of one or more disorders associated with thromboses, embolisms, hypercoagulability or fibrotic changes.
    Type: Grant
    Filed: March 1, 2016
    Date of Patent: June 27, 2017
    Assignee: SANOFI
    Inventors: Christopher Kallus, Mark Broenstrup, Andreas Evers, Anja Globisch, Herman Schreuder, Michael Wagner
  • MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIA
    Publication number: 20160251324
    Abstract: The invention relates to compounds of the formula (I) which are inhibitors of activated thrombin-activable fibrinolysis inhibitor. The compounds of the formula I are suitable for producing medicaments for prophylaxis, secondary prevention and treatment of one or more disorders associated with thromboses, embolisms, hypercoagulability or fibrotic changes.
    Type: Application
    Filed: March 1, 2016
    Publication date: September 1, 2016
    Inventors: Christopher KALLUS, Mark BROENSTRUP, Andreas EVERS, Anja GLOBISCH, Herman SCHREUDER, Michael WAGNER
  • Macrocyclic Urea Derivatives as Inhibitors of TAFIa, Their Preparation and Their Use as Pharmaceuticals
    Publication number: 20160137618
    Abstract: The present invention relates to macrocydic urea derivatives of the formula I (I) in which R1, R2, R3, V and Y are as defined below. The compounds of the formula I are inhibitors of the enzyme TAFIa (activated thrombin-activatable fibrinolysis inhibitor). The invention further relates to the process for the preparation of the compounds of formula I and to the use thereof as medicaments.
    Type: Application
    Filed: June 5, 2014
    Publication date: May 19, 2016
    Inventors: Andreas Evers, Christopher Kallus, Michael Wagner, Hermut Wehlan
  • Macrocyclic urea and sulfamide derivatives as inhibitors of TAFIa
    Patent number: 9309207
    Abstract: The invention relates to compounds of the formula (I) which are inhibitors of activated thrombin-activable fibrinolysis inhibitor. The compounds of the formula I are suitable for producing medicaments for prophylaxis, secondary prevention and treatment of one or more disorders associated with thromboses, embolisms, hypercoagulability or fibrotic changes.
    Type: Grant
    Filed: July 28, 2015
    Date of Patent: April 12, 2016
    Assignee: SANOFI
    Inventors: Christopher Kallus, Mark Broenstrup, Andreas Evers, Anja Globisch, Herman Schreuder, Michael Wagner
  • MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIA
    Publication number: 20160024033
    Abstract: The invention relates to compounds of the formula (I) which are inhibitors of activated thrombin-activable fibrinolysis inhibitor. The compounds of the formula I are suitable for producing medicaments for prophylaxis, secondary prevention and treatment of one or more disorders associated with thromboses, embolisms, hypercoagulability or fibrotic changes.
    Type: Application
    Filed: July 28, 2015
    Publication date: January 28, 2016
    Inventors: Christopher KALLUS, Mark BROENSTRUP, Andreas EVERS, Anja GLOBISCH, Herman SCHREUDER, Michael WAGNER
  • Biaryl-propionic acid derivatives and their use as pharmaceuticals
    Patent number: 9199947
    Abstract: The present invention relates to compounds of the formula I, wherein X, R, R1, R2, D, E1, E2, E3, E4, G1, G2, G3 and G4 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: March 27, 2014
    Date of Patent: December 1, 2015
    Assignee: Sanofi
    Inventors: Sven Ruf, Thorsten Sadowski, Klaus Wirth, Herman Schreuder, Christian Buning, Christopher Kallus, Hartmut Strobel, Hermut Wehlan
  • Biaryl-propionic acid derivatives and their use as pharmaceuticals
    Patent number: 9150526
    Abstract: The present invention relates to compounds of the formula I, wherein X, R, R1, R2, D, E1, E2, E3, E4, G1, G2, G3 and G4 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: March 27, 2014
    Date of Patent: October 6, 2015
    Assignee: Sanofi
    Inventors: Sven Ruf, Thorsten Sadowski, Klaus Wirth, Herman Schreuder, Christian Buning, Christopher Kallus, Hartmut Strobel, Hermut Wehlan
  • Macrocyclic urea and sulfamide derivatives as inhibitors of TAFIa
    Patent number: 9126955
    Abstract: The invention relates to compounds of the formula (I) which are inhibitors of activated thrombin-activable fibrinolysis inhibitor. The compounds of the formula I are suitable for producing medicaments for prophylaxis, secondary prevention and treatment of one or more disorders associated with thromboses, embolisms, hypercoaguability or fibrotic changes.
    Type: Grant
    Filed: March 26, 2014
    Date of Patent: September 8, 2015
    Assignee: SANOFI
    Inventors: Christopher Kallus, Mark Broenstrup, Andreas Evers, Anja Globisch, Herman Schreuder, Michael Wagner
  • Biaryl-Propionic Acid Derivatives and their Use as Pharmaceuticals
    Publication number: 20140296296
    Abstract: The present invention relates to compounds of the formula I, wherein X, R, R1, R2, D, E1, E2, E3, E4, G1, G2, G3 and G4 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.
    Type: Application
    Filed: March 27, 2014
    Publication date: October 2, 2014
    Inventors: Sven Ruf, Thorsten Sadowski, Klaus Wirth, Herman Schreuder, Christian Buning, Christopher Kallus, Hartmut Strobel, Hermut Wehlan
  • Biaryl-propionic acid derivatives and their use as pharmaceuticals
    Publication number: 20140296239
    Abstract: The present invention relates to compounds of the formula I, wherein X, R, R1, R2, D, E1, E2, E3, E4, G1, G2, G3 and G4 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.
    Type: Application
    Filed: March 27, 2014
    Publication date: October 2, 2014
    Applicant: SANOFI
    Inventors: Sven Ruf, Thorsten Sadowski, Klaus Wirth, Herman Schreuder, Christian Buning, Christopher Kallus, Hartmut Strobel, Hermut Wehlan
  • MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIA
    Publication number: 20140206760
    Abstract: The invention relates to compounds of the formula (I) which are inhibitors of activated thrombin-activable fibrinolysis inhibitor. The compounds of the formula I are suitable for producing medicaments for prophylaxis, secondary prevention and treatment of one or more disorders associated with thromboses, embolisms, hypercoaguability or fibrotic changes.
    Type: Application
    Filed: March 26, 2014
    Publication date: July 24, 2014
    Applicant: SANOFI
    Inventors: Christopher Kallus, Mark Broenstrup, Andreas Evers, Anja Globisch, Herman Schreuder, Michael Wagner
  • Macrocyclic urea and sulfamide derivatives as inhibitors of tafia
    Patent number: 8722655
    Abstract: The invention relates to compounds of the formula (I) which are inhibitors of activated thrombin-activable fibrinolysis inhibitor. The compounds of the formula I are suitable for producing medicaments for prophylaxis, secondary prevention and treatment of one or more disorders associated with thromboses, embolisms, hypercoagulability or fibrotic changes.
    Type: Grant
    Filed: October 8, 2013
    Date of Patent: May 13, 2014
    Assignee: Sanofi
    Inventors: Christopher Kallus, Mark Broenstrup, Andreas Evers, Anja Globisch, Herman Schreuder, Michael Wagner
  • Imidazole derivatives used as TAFIa inhibitors
    Patent number: 8710232
    Abstract: The present invention relates to compounds of formula (I) which are inhibitors of the activated thrombin-activatable fibrinolysis inhibitor. The compounds of formula (I) are suited for producing medicaments for the prevention and treatment of diseases accompanied by thromboses, embolisms, hypercoagulability or fibrotic changes.
    Type: Grant
    Filed: October 23, 2006
    Date of Patent: April 29, 2014
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Christopher Kallus, Holger Heitsch, Andreas Lindenschmidt, Sven Grueneberg, Hauke Szillat
  • MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIA
    Publication number: 20140039011
    Abstract: The invention relates to compounds of the formula (I) which are inhibitors of activated thrombin-activable fibrinolysis inhibitor. The compounds of the formula I are suitable for producing medicaments for prophylaxis, secondary prevention and treatment of one or more disorders associated with thromboses, embolisms, hypercoagulability or fibrotic changes.
    Type: Application
    Filed: October 8, 2013
    Publication date: February 6, 2014
    Applicant: SANOFI
    Inventors: Christopher Kallus, Mark Broenstrup, Andreas Evers, Anja Globisch, Herman Schreuder, Michael Wagner
  • Macrocyclic urea and sulfamide derivatives as inhibitors of TAFIa
    Patent number: 8580777
    Abstract: The invention relates to compounds of the formula (I) which are inhibitors of activated thrombin-activable fibrinolysis inhibitor. The compounds of the formula I are suitable for producing medicaments for prophylaxis, secondary prevention and treatment of one or more disorders associated with thromboses, embolisms, hypercoagulability or fibrotic changes.
    Type: Grant
    Filed: May 22, 2009
    Date of Patent: November 12, 2013
    Assignee: Sanofi
    Inventors: Christopher Kallus, Mark Broenstrup, Andreas Evers, Anja Globisch, Herman Schreuder, Michael Wagner
  • Urea and sulfamide derivatives as inhibitors of TAFIa
    Patent number: 8389764
    Abstract: The invention relates to compounds of the formula I as defined herein, which are inhibitors of activated thrombin-activatable fibrinolysis inhibitor. The compounds of the formula I are suitable for manufacturing medicaments for the prophylaxis, secondary prevention and therapy of one or more disorders which are associated with thromboses, embolisms, hypercoagulability or fibrotic changes.
    Type: Grant
    Filed: June 8, 2009
    Date of Patent: March 5, 2013
    Assignee: Sanofi
    Inventors: Christopher Kallus, Mark Broenstrup, Werngard Czechtizky, Andreas Evers, Markus Follmann, Nis Halland, Herman Schreuder
  • Imidazole derivatives as inhibitors of TAFIa
    Patent number: 8044208
    Abstract: The present invention is directed to a compound of formula I: or any stereoisomeric form of the compound of the formula I or a mixture of these forms in any ratio or a physiologically acceptable salt of the compound of the formula I which inhibit the enzyme TAFIa (activated thrombin-activatable fibrinolysis inhibitor), and to a process for their preparation and to their use to treat described diseases where the substituents are as described in the specification.
    Type: Grant
    Filed: April 14, 2008
    Date of Patent: October 25, 2011
    Assignee: Sanofi-Aventis
    Inventors: Christopher Kallus, Holger Heitsch, Volkmar Wehner
  • MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIa
    Publication number: 20110178130
    Abstract: The invention relates to compounds of the formula (I) which are inhibitors of activated thrombin-activable fibrinolysis inhibitor. The compounds of the formula I are suitable for producing medicaments for prophylaxis, secondary prevention and treatment of one or more disorders associated with thromboses, embolisms, hypercoagulability or fibrotic changes.
    Type: Application
    Filed: May 22, 2009
    Publication date: July 21, 2011
    Applicant: SANOFI-AVENTIS
    Inventors: Christopher Kallus, Mark Broenstrup, Andreas Evers, Anja Globisch, Herman Schreuder, Michael Wagner
  • UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIa
    Publication number: 20100035930
    Abstract: The invention relates to compounds of the formula I as defined herein, which are inhibitors of activated thrombin-activatable fibrinolysis inhibitor. The compounds of the formula I are suitable for manufacturing medicaments for the prophylaxis, secondary prevention and therapy of one or more disorders which are associated with thromboses, embolisms, hypercoagulability or fibrotic changes.
    Type: Application
    Filed: June 8, 2009
    Publication date: February 11, 2010
    Applicant: SANOFI-AVENTIS
    Inventors: Christopher KALLUS, Mark BROENSTRUP, Werngard CZECHTIZKY, Andreas EVERS, Markus FOLLMANN, Nis HALLAND, Herman SCHREUDER